Heart Disease in Myasthenia Gravis
Acta Neurol Scand 70:176-184, Hofstad,H.,et al, 1984
Ventilatory Failure in Myasthenia Gravis
JNNP 45:217-222, Ferguson,I.T.,et al, 1982
Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Incidence and Mortality Rates of Myasthenia Gravis and Myasthenic Crisis in US Hospitals
Neurol 72:1548-1554, Alshekhlee,A.,et al, 2009
Causes of Death Among Patients with Myasthenia Gravis in Norway Between 1951 and 2001
JNNP 77:203-207, Owe,J.F.,et al, 2006
Intensive Care of the Myasthenic Patient
Neurol 48 (Suppl 5) :S70-S75997., Mayer,S.A., 1997
Myasthenic Crisis:Clinical Features, Mortality, Comp, & Risk Factors for Prolonged Intubation
Neurol 48:1253-1254, Thomas,C.E.,et al, 1997
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Acute Neuromuscular Respiratory Paralysis
JNNP 56:334-343, Hughes,R.A.C.&Bihari,D., 1993
Myasthenia Gravis in Mothers and Their Newborns
Clin Obstet Gynecol 34:82-99, Plauche,W.C., 1991
Middle Ear Effusions and Myasthenic Gravis
J Laryn and Otology, 102:169-1701988., O'Reilly,B.J., 1988
Clinical Pathological Conference
Giant-cell Arteritis of Temporal Artery (temporal arteritis) , Case Record 35-1977, NEJM 297:4927., , 1977